Skip to main content

Table 2 Baseline clinical and viro-immunological characteristics of 67 HIV-infected naive pregnant women with valuable results from the HIV genotypic drug-resistance assay

From: HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania

Characteristics HIV-infected pregnant women with a valuable result at HIV genotype n° 67 p value
  Women with wild-type genotype n° 59 Women with any drug-resistant mutation n°8  
Age, years, mean ± SD 28.6 ± 5.3 30.6 ± 4.7 0.3
Gestational age at enrolment, week, mean ± SD; 20.8 ± 4.9 17.2 ± 4.4 0.06
Height at screening, cm, mean ± SD 155.9 ± 5.9 155.3 ± 3.2 0.8
Race/ethnicity,    
     Black African, n. (%) 59 (100) 8 (100) 1
Education, n. (%)    0.3
    Primary school 36 (61) 7 (87.5)  
    Secondary school 10 (16.9) 1 (12.5)  
    Other or unknown 13 (22) 0 (0)  
Number of pregnancies, mean ± SD 2.9 ±1.5 2.6 ±1.8 0.6
Number of deliveries, mean ± SD 1.8 ±1.5 1.6 ±1.8 0.7
Number of children, mean ± SD 1.4 ±1.2 1.6 ±1.8 0.6
HIV risk factor, n° (%)    
     Unprotected heterosexual relationship 59 (100) 8 (100) 1
WHO stage, n° (%)    0.9
    1 35 (59) 4 (50)  
    2 15 (25) 3 (37.5)  
    3 8 (14) 1 (12.5)  
    4 1 (2) 0  
MedianCD4+ cells at enrolment /μL (IQR) 406 (297-530) 396 (240-461) 0.7
Days since HIV diagnosis, mean ± SD 102 ±182 117 ±28 0.8
Median log10 HIV RNA copies/mL (IQR) 9.28 (4.82-10.71) 7.94 (3.58-9.49) 0.3
Eligible for HAART, n (%) 9 (15.5) 2 (25) 0.5
Positive VDRL assay, n (%) 1 (1.9) 1 (12.5) 0.1
  1. Note. Demographic, clinical and viro-immunological data were analyzed with Chi- square test and univariate analysis (significant level was set at 0.05).